OXFORD BIOMEDICA Stock Swiss Exchange
Equities
OXB
GB0006648157
Biotechnology & Medical Research
Sales 2023 | 89.54M 112M | Sales 2024 * | 131M 164M | Capitalization | 328M 411M |
---|---|---|---|---|---|
Net income 2023 | -157M -197M | Net income 2024 * | -35M -43.9M | EV / Sales 2023 | 2.38 x |
Net cash position 2023 * | 49.23M 61.75M | Net cash position 2024 * | 13.8M 17.31M | EV / Sales 2024 * | 2.41 x |
P/E ratio 2023 |
-1.35
x | P/E ratio 2024 * |
-9.59
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.81% |
Latest transcript on OXFORD BIOMEDICA
Managers | Title | Age | Since |
---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 23-03-26 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 17-08-28 |
Chairman | 68 | 20-06-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 23-04-30 |
Chairman | 68 | 20-06-23 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 16-05-31 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |